B cell Repertoire Recovery Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Information from Minimal Residual Disease (MRD) Testing | Synapse
March 3, 2026
B cell Repertoire Recovery Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Information from Minimal Residual Disease (MRD) Testing
Key Points
B cell repertoire recovery shows significant improvement post-transplantation, revealing immune system restoration.
Key evidence indicates that tracking minimal residual disease levels correlates with enhanced recovery outcomes.
Assessment using minimal residual disease testing provides insights into immune recovery after treatment.
Findings suggest ongoing monitoring of B cell repertoire could inform patient management and therapy adjustments.